Indianapolis — Here are the eight Eli Lilly and Co. drugs the firm hopes to launch by the end of 2004, pending regulatory approval, with expected launch dates:
Forteo: A bone-building agent to reverse osteoporosis. 2002.
Cialis: Developed jointly with Bothell, Wash.-based ICOS Corp. to treat male erectile dysfunction. Late 2002.
Atomexetine: A nonstimulant to treat attention- deficit disorder in children. Late 2002.
Duloxetine: For depression. Late 2002.
Olanzipine and Fluoxetine combination: For treatment-resistant depression and psychotic depression. Submission for regulatory approval expected as early as 2002.
Alimta: For treatment of mesothelioma, a rare lung cancer linked to asbestos exposure. Submission for approval expected mid-2002.
Duloxetine: For stress urinary incontinence. Submission for approval late 2002.
PKC beta inhibitor: For treatment of diabetic macular edema and diabetic retinopathy, the leading cause of blindness in people under the age of 65. Submission for approval 2003.